Sanaria’s PFSPZ vaccine achieves durable protection against heterologous malaria infection in a clinical trial


(newsPRos) In a PNAS report published today, 'Sanaria's PfSPZ Vaccine Achieves Durable Protection Against Heterologous Malaria Infection in a Clinical Trial,' investigators from NIAID, NIH and the U. Maryland found that three doses of Sanaria® PfSPZ vaccine provided protection in clinical trial subjects who were exposed to a malaria strain different than the vaccine strain eight months after the last dose of vaccine. 'An enormously important finding,' says world-renowned vaccinologist Dr. Stanley Plotkin.

Leave A Reply

Your email address will not be published.